Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd is poised for significant revenue growth due to a recent study that could enable Glioblastoma (GBM) patients to start treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company is also expected to see a rise in active patients driven by growth in the U.S. and Germany, which serve as key markets and are indicative of future revenue trajectories. Additionally, the introduction of new markets within the next 12-18 months is anticipated to further enhance revenue streams, supplementing existing growth drivers.

Bears say

The financial outlook for NovoCure indicates a significant decline in EBITDA as revenue is expected to ramp up gradually over the upcoming quarters. Analysts estimate that the company may only reach breakeven levels in EBITDA by 2027, suggesting a prolonged period of financial strain. This projected timeline for achieving profitability raises concerns about the sustainability of the company's operations amid ongoing investments in its pipeline and product development.

Novocure (NVCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 7 analysts, Novocure (NVCR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.